Matches in SemOpenAlex for { <https://semopenalex.org/work/W2788394845> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2788394845 endingPage "e962" @default.
- W2788394845 startingPage "e955" @default.
- W2788394845 abstract "Objective To assess safety, tolerability, and efficacy of the antigen-specific immunotherapy ATX-MS-1467 in participants with relapsing multiple sclerosis using different treatment protocols to induce tolerance. Methods Two open-label trials in adult participants with relapsing multiple sclerosis were conducted. Study 1 was a multicenter, phase 1b safety evaluation comparing intradermal (i.d.) (cohort 1) with subcutaneous (cohort 2) administration in 43 participants. Both cohorts received ATX-MS-1467 dosed at 25, 50, 100, 400, and 800 μg at 14-day intervals over 8 weeks, followed by 8 weeks with 4 additional 800-μg doses at 14-day intervals and 32 weeks off study medication. Study 2 was a phase 2a, multicenter, single-arm trial enrolling 37 participants. ATX-MS-1467 was titrated from 50 μg i.d. on day 1 to 200 μg on day 15 and 800 μg on day 29 followed by biweekly administration of 800 μg for 16 weeks and 16 weeks off study medication. Efficacy was evaluated on MRI parameters and clinical variables. Safety endpoints included treatment-emergent adverse events and injection-site reactions. Results In study 1, there was a significant decrease in new/persisting T1 gadolinium-enhanced (GdE) lesions in cohort 1 from baseline to week 16, returning to baseline values at week 48. In study 2, the number of T1 GdE lesions were significantly reduced on treatment and remained reduced at study completion. Safety results were unremarkable in both studies. Conclusion Relatively slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions and a sustained effect post treatment. Further trials of ATX-MS-1467 are warranted. Classification of evidence This work provides Class IV evidence that for patients with relapsing multiple sclerosis, slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions." @default.
- W2788394845 created "2018-03-06" @default.
- W2788394845 creator A5000364062 @default.
- W2788394845 creator A5007196021 @default.
- W2788394845 creator A5007468017 @default.
- W2788394845 creator A5019920066 @default.
- W2788394845 creator A5021866075 @default.
- W2788394845 creator A5047337717 @default.
- W2788394845 date "2018-02-21" @default.
- W2788394845 modified "2023-10-16" @default.
- W2788394845 title "Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis" @default.
- W2788394845 cites W1833759296 @default.
- W2788394845 cites W1907524553 @default.
- W2788394845 cites W1965976393 @default.
- W2788394845 cites W1967904326 @default.
- W2788394845 cites W2012724478 @default.
- W2788394845 cites W2034651911 @default.
- W2788394845 cites W2042166711 @default.
- W2788394845 cites W2049566645 @default.
- W2788394845 cites W2065619967 @default.
- W2788394845 cites W2068848860 @default.
- W2788394845 cites W2081212861 @default.
- W2788394845 cites W2081954982 @default.
- W2788394845 cites W2085721994 @default.
- W2788394845 cites W2107074680 @default.
- W2788394845 cites W2118277450 @default.
- W2788394845 cites W2122545833 @default.
- W2788394845 cites W2130136130 @default.
- W2788394845 cites W2140395003 @default.
- W2788394845 cites W2285153579 @default.
- W2788394845 doi "https://doi.org/10.1212/wnl.0000000000005118" @default.
- W2788394845 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29467307" @default.
- W2788394845 hasPublicationYear "2018" @default.
- W2788394845 type Work @default.
- W2788394845 sameAs 2788394845 @default.
- W2788394845 citedByCount "62" @default.
- W2788394845 countsByYear W27883948452018 @default.
- W2788394845 countsByYear W27883948452019 @default.
- W2788394845 countsByYear W27883948452020 @default.
- W2788394845 countsByYear W27883948452021 @default.
- W2788394845 countsByYear W27883948452022 @default.
- W2788394845 countsByYear W27883948452023 @default.
- W2788394845 crossrefType "journal-article" @default.
- W2788394845 hasAuthorship W2788394845A5000364062 @default.
- W2788394845 hasAuthorship W2788394845A5007196021 @default.
- W2788394845 hasAuthorship W2788394845A5007468017 @default.
- W2788394845 hasAuthorship W2788394845A5019920066 @default.
- W2788394845 hasAuthorship W2788394845A5021866075 @default.
- W2788394845 hasAuthorship W2788394845A5047337717 @default.
- W2788394845 hasBestOaLocation W27883948452 @default.
- W2788394845 hasConcept C121608353 @default.
- W2788394845 hasConcept C126322002 @default.
- W2788394845 hasConcept C141071460 @default.
- W2788394845 hasConcept C197934379 @default.
- W2788394845 hasConcept C201903717 @default.
- W2788394845 hasConcept C203014093 @default.
- W2788394845 hasConcept C2777701055 @default.
- W2788394845 hasConcept C2778375690 @default.
- W2788394845 hasConcept C2780640218 @default.
- W2788394845 hasConcept C535046627 @default.
- W2788394845 hasConcept C71924100 @default.
- W2788394845 hasConcept C72563966 @default.
- W2788394845 hasConceptScore W2788394845C121608353 @default.
- W2788394845 hasConceptScore W2788394845C126322002 @default.
- W2788394845 hasConceptScore W2788394845C141071460 @default.
- W2788394845 hasConceptScore W2788394845C197934379 @default.
- W2788394845 hasConceptScore W2788394845C201903717 @default.
- W2788394845 hasConceptScore W2788394845C203014093 @default.
- W2788394845 hasConceptScore W2788394845C2777701055 @default.
- W2788394845 hasConceptScore W2788394845C2778375690 @default.
- W2788394845 hasConceptScore W2788394845C2780640218 @default.
- W2788394845 hasConceptScore W2788394845C535046627 @default.
- W2788394845 hasConceptScore W2788394845C71924100 @default.
- W2788394845 hasConceptScore W2788394845C72563966 @default.
- W2788394845 hasIssue "11" @default.
- W2788394845 hasLocation W27883948451 @default.
- W2788394845 hasLocation W27883948452 @default.
- W2788394845 hasLocation W27883948453 @default.
- W2788394845 hasLocation W27883948454 @default.
- W2788394845 hasOpenAccess W2788394845 @default.
- W2788394845 hasPrimaryLocation W27883948451 @default.
- W2788394845 hasRelatedWork W1490050402 @default.
- W2788394845 hasRelatedWork W1990197915 @default.
- W2788394845 hasRelatedWork W2087016115 @default.
- W2788394845 hasRelatedWork W2305775430 @default.
- W2788394845 hasRelatedWork W2427186628 @default.
- W2788394845 hasRelatedWork W2465571689 @default.
- W2788394845 hasRelatedWork W2768193050 @default.
- W2788394845 hasRelatedWork W3000123036 @default.
- W2788394845 hasRelatedWork W3191427281 @default.
- W2788394845 hasRelatedWork W4311628015 @default.
- W2788394845 hasVolume "90" @default.
- W2788394845 isParatext "false" @default.
- W2788394845 isRetracted "false" @default.
- W2788394845 magId "2788394845" @default.
- W2788394845 workType "article" @default.